27 Dec 2023 , 03:02 PM
Aurobindo Pharma Ltd’s subsidiary, Eugia Pharma Specialities Ltd, secures final approval from the USFDA for manufacturing and marketing Posaconazole Injection.
The approved product, bioequivalent to Merck Sharp & Dohme LLC’s Noxafil Injection, is in the strength of 300 mg/16.7 mL (18 mg/mL), Single-Dose Vial.
The launch of the product is scheduled for December 2023, targeting an estimated market size of US$ 25.4 million for the 12 months ending October 2023, according to IQVIA.
This approval marks the 173rd ANDA approval from Eugia Pharma Specialities Group (EPSG), which specializes in manufacturing both oral and sterile specialty products.
Posaconazole Injection is indicated for prophylaxis against invasive Aspergillus and Candida infections in severely immunocompromised patients, including hematopoietic stem cell transplant recipients with graft-versus-host disease and those with hematologic malignancies undergoing chemotherapy-induced prolonged neutropenia.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.